Clinical trials: Osteoporosis Postmenopausal
Osteopenia
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture.
- Trial name
- NCT01292187
- Testing
- Oral calcitonin at dinnertime, Oral calcitonin at bedtime
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis, Postmenopausal
Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes
Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatment adherence (including…
- Trial name
- NCT03435094
- Testing
- Binosto 70Mg Effervescent Tablet, Fosamax 70Mg Tablet
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Labatec Pharma SA
Osteoporosis
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
The purpose of this study is to compare the efficacy and safety of Denosumab 60 mg produced by AryoGen Pharmed and Amgen Denosumab 60 mg among osteoporotic postmenopausal women.
- Trial name
- NCT03293108
- Testing
- Denosumab, calcium, vitamin D
- Where
- Iran
- Volunteers
- 190 people
- Sponsor
- AryoGen Pharmed Co.
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteoporosis
To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women
The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM group) versus Weekly Oral risedronate(Risenexsplus group) in Korean postmenopausal osteoporotic women(Phase IV)
- Trial name
- NCT01904110
- Testing
- Risedronate/Cholecalciferol combination(montly), Risedronate/Cholecalciferol combination(weekly)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Hanlim Pharm. Co., Ltd.